Hyderabad Paediatrician Resigns from Indian Academy of Paediatrics Over ORS Marketing Controversy
In a significant development highlighting tensions between medical ethics and commercial interests, Hyderabad-based paediatrician Dr Sivaranjani Santosh has resigned from the Indian Academy of Paediatrics (IAP). The resignation comes after a prolonged dispute concerning the marketing of sugar-rich beverages as oral rehydration solutions (ORS) and what she describes as a lack of institutional support during legal challenges.
The Core Issue: Sugar-Rich Drinks Masquerading as Medical ORS
Dr Santosh had been raising concerns about certain commercial products, specifically mentioning ORSL, being marketed as oral rehydration solutions despite containing excessive sugar levels. Her advocacy gained traction when the Food Safety and Standards Authority of India (FSSAI) intervened in October last year. The regulatory body banned the use of the 'ORS' label on beverages that did not meet World Health Organization (WHO) standards, deeming such branding misleading and a potential health risk to children.
The FSSAI action was a direct response to the misleading marketing practices that Dr Santosh had highlighted. Many of these products contained sugar amounts far exceeding those in genuine medical-grade ORS, which are specifically formulated to rehydrate patients suffering from diarrhoea without exacerbating their condition through excessive sugar intake.
Legal Pressure and Institutional Response
Following her public criticism, Dr Santosh received legal notices from pharmaceutical companies manufacturing these products. It was the IAP's response—or lack thereof—to these legal threats that ultimately prompted her resignation.
"Enough is enough. This was the last nail in the coffin. I cannot take this toxicity any more," Dr Santosh told TOI after submitting her resignation. "If I have to choose between children and the IAP, I will choose the children."
While acknowledging the IAP as a "great organization," she expressed disappointment that its leadership chose not to condemn the legal notice issued against her. Instead, the organization released a statement emphasizing the safety of sucralose—an artificial sweetener used in some products—without warning parents about potential risks of prolonged use.
Rebranding and Continued Concerns
After the FSSAI ban, the manufacturer launched a rebranded version called ERZL. However, Dr Santosh continued her opposition, arguing that the new name closely resembled ORS and could still mislead parents seeking proper medical treatment for their children.
"So many paediatricians have asked the IAP leadership to at least listen to me, and voted in favour of asking the company concerned to rebrand its ERZL so that it doesn't resemble ORS, but the leadership didn't pay heed," she revealed.
Recent IAP Statement and Broader Implications
Earlier this month, the IAP did release a statement clarifying that commercial electrolyte drinks cannot replace ORS for treating diarrhoea and urging consumers to use them cautiously. However, this came too late to address Dr Santosh's specific concerns about institutional support during her legal challenges.
This resignation highlights ongoing tensions within medical organizations regarding how to balance commercial interests with patient advocacy. It also underscores the challenges healthcare professionals face when speaking out against powerful industry players, even when backed by regulatory actions like the FSSAI ban.
The case raises important questions about institutional support for members facing legal pressure for their professional opinions and advocacy work. As Dr Santosh's departure demonstrates, when medical professionals feel unsupported by their professional organizations in matters of patient safety, it can lead to significant ruptures within the medical community.
